[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Arthur A. Levin, Ph.D., a director of Stoke Therapeutics, reported equity awards and ownership changes on Form 4. On 09/30/2025 he became the beneficial owner of 1,211 restricted stock units (RSUs) that represent the right to receive one share each upon settlement. The filing shows these RSUs were recorded with a $0 price and are tied to settlement in common stock.

The report indicates 1,211 shares associated with the RSUs are held directly and that following the reported transaction the reporting person beneficially owned 3,631 shares directly and 17,979 shares indirectly through the Butler-Levin Revocable Trust, where he serves as trustee. The RSU award vests in quarterly 1/4 installments on the last day of March, June, September, and December, subject to continued service, with an indicated settlement date of 12/31/2025 for the reported tranche.

Positive

• Director received 1,211 RSUs representing alignment with shareholder interests through equity compensation
• Clear vesting schedule: RSUs vest 1/4 quarterly with settlement referenced as 12/31/2025, providing transparency on timing

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine director equity vesting consistent with standard compensation governance; no unusual related-party transfers disclosed.

The Form 4 documents a typical director equity award vesting event. The filing shows direct ownership from vested RSUs and a larger indirect position held via a revocable trust, which is common for governance and estate planning. The quarterly 1/4 vesting schedule and $0 reported price reflect standard time-based RSU grants rather than market purchases or sales. There are no disclosures here of loans, pledges, or transfers that would raise governance flags.

Securities Analyst

TL;DR: Small-scale insider vesting; immaterial to capital structure but increases reported insider alignment modestly.

The transaction increases the reporting person’s direct stake by 1,211 shares, bringing direct beneficial ownership to 3,631 shares and indirect ownership to 17,979 shares via the Butler-Levin Revocable Trust. The RSUs settle into common stock and are recorded at $0, indicating grant/vesting rather than an open-market trade. For most investors this is a routine, non-dilutive compensation event that does not materially affect outstanding share count or cash flow.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

LEVIN ARTHUR A

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		M		1,211	A	$0	3,631	D
Common Stock								17,979	I	Arthur A. Levin, Ph.D., Trustee, Butler-Levin Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/30/2025		M			1,211	(2)	12/31/2025	Common Stock	1,211	$0	1,211	D

Explanation of Responses:

1. Each Restricted Stock Unit represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

2. The award vested or vests as to 1/4 of the total award quarterly on the last day of March, June, September, and December, subject to the reporting person's continued service to the issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Arthur A. Levin report on Form 4 for STOK?

He reported the acquisition/vesting of 1,211 restricted stock units (RSUs) on 09/30/2025 which represent the right to receive one share each upon settlement.

How many STOK shares does Arthur A. Levin beneficially own after the transaction?

The filing shows 3,631 shares directly and 17,979 shares indirectly through the Butler-Levin Revocable Trust.

What is the vesting schedule for the RSUs reported on the Form 4?

The RSU award vests as to 1/4 of the total award quarterly on the last day of March, June, September, and December, subject to continued service.

What is the settlement date referenced for the vested RSUs?

The filing references a settlement/related date of 12/31/2025 for the reported RSU tranche.

Was there any cash paid for the RSUs in this transaction?

No cash was paid; the report lists a $0 price for the RSUs, indicating a vesting/grant event rather than a cash purchase.